StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Avalo Therapeutics Inc. (AVTX)

Fri, 16 Oct 2026 07:59:25 -0400

H.C. Wainwright analyst Mitchel Kapoor reiterated a Buy rating and $30.00 price target on Avalo Therapeutics Inc. (NASDAQ: AVTX).

The analyst commented: "A ≥25-point placebo-adjusted HiSCR75 benefit for lutikizumab would pressure abdakibart’s commercial positioning, particularly after prior biologic failure. AbbVie (ABBV; not rated) has guided to 16-week Phase 3 hidradenitis suppurativa (HS) results later in 2026 from INTREPID, which enrolled 1,400 patients. We expect a positive study and favor mid-November for top-line release, with December still possible. Our threshold for competitive differentiation is ~45-50% HiSCR75 with ≥25 points of benefit over placebo, accompanied by pain and drainage improvement. Monthly abdakibart produced

Form 4 Avalo Therapeutics, Inc. For: Sep 30 Filed by: Philip Ron M

Fri, 02 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261002/27142431.html

Form 4 Avalo Therapeutics, Inc. For: Sep 30 Filed by: Lind Kevin Robert

Fri, 02 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261002/27142440.html

Form 4 Avalo Therapeutics, Inc. For: Sep 30 Filed by: Jain Rita

Fri, 02 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261002/27142442.html

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Tue, 29 Sep 2026 16:01:00 -0400

WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 101,600 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The Options were granted on

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Tue, 29 Sep 2026 16:01:00 -0400

The Options were granted on

Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

Wed, 23 Sep 2026 07:00:00 -0400

WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vienna, Austria from September 30-October 3, 2026.

EADV Congress 2026 Presentation Details:

Late-Breaker Oral Presentation:

Title: Efficacy and Safety of Abdakibart (ABD), a Humanized High Affinity and Potency IgG4 Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa at Week 16; IHS4

Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

Wed, 23 Sep 2026 07:00:00 -0400

EADV Congress 2026 Presentation Details:

Late-Breaker Oral Presentation:

Title: Efficacy and Safety of Abdakibart (ABD), a Humanized High Affinity and Potency IgG4 Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa at Week 16; IHS4

Form 4 Avalo Therapeutics, Inc. For: Sep 16 Filed by: Sullivan Christopher Ryan

Fri, 18 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260918/27080634.html

Avalo Therapeutics (AVTX) Reiterated at Overweight by Cantor Fitzgerald

Wed, 16 Sep 2026 07:39:21 -0400

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Avalo Therapeutics Inc. (NASDAQ: AVTX).

The analyst commented, "IL-1 inhibition is the mechanism our KOLs are most excited about next, offering broader upstream immunosuppression than IL-17 blockade and showing efficacy in prior IL-17 failures. Dr. Cameron picked Avalo's (AVTX, OW, PA) IL-1b abdakibart as his preferred drug in HS."

For an analyst ratings summary and ratings history on Avalo Therapeutics Inc. click here. For more ratings news on Avalo Therapeutics Inc. click here.

Shares of Avalo Therapeutics Inc. closed at $16.07 yesterday.

Form 4 Avalo Therapeutics, Inc. For: Sep 10 Filed by: Sullivan Christopher Ryan

Fri, 11 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260911/27052980.html

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 16:05:00 -0400

WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The Options were granted on

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 16:05:00 -0400

The Options were granted on

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 07:00:00 -0400

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Cantor Global Healthcare Conference 2026

Fireside Chat
September 10, 2026, at 8:00 am ET

Morgan Stanley 24th Annual Global Healthcare Conference

1x1 meetings only
September 16, 2026

H.C. Wainwright 28th Annual Global Investment Conference

Presentation
September 16, 2026, at 8:30 am ET

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 07:00:00 -0400

Cantor Global Healthcare Conference 2026

Fireside Chat
September 10, 2026, at 8:00 am ET

Morgan Stanley 24th Annual Global Healthcare Conference

1x1 meetings only
September 16, 2026

H.C. Wainwright 28th Annual Global Investment Conference

Presentation
September 16, 2026, at 8:30 am ET

Form 4 Avalo Therapeutics, Inc. For: Aug 17 Filed by: Sullivan Christopher Ryan

Tue, 25 Aug 2026 19:03:00 -0400

si-local-file:///var/storage/secattach/20260825/26975956.html

Form 4 Avalo Therapeutics, Inc. For: Aug 17 Filed by: Doyle Mittie

Tue, 25 Aug 2026 19:03:00 -0400

si-local-file:///var/storage/secattach/20260825/26975991.html

Form 4 Avalo Therapeutics, Inc. For: Aug 17 Filed by: Sullivan Christopher Ryan

Wed, 19 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260819/26950140.html

Form 4 Avalo Therapeutics, Inc. For: Aug 17 Filed by: Doyle Mittie

Wed, 19 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260819/26950142.html

Form 144 Avalo Therapeutics, Inc. Filed by: Sullivan Christopher Ryan

Tue, 18 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260818/26944529.html

Form 144 Avalo Therapeutics, Inc. Filed by: Doyle Mittie

Mon, 17 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260817/26938630.html

Form 144 Avalo Therapeutics, Inc. Filed by: Sullivan Christopher Ryan

Mon, 17 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260817/26938602.html

Form 144 Avalo Therapeutics, Inc. Filed by: Sullivan Christopher Ryan

Mon, 17 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260817/26938191.html

Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932190.html

Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932089.html